Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 20/20 | 0.68 |
| ▸ | GABRP | O00591 | 1/20 | 0.66 |
| ▸ | GABRD | O14764 | 1/20 | 0.66 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.66 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.66 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.66 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.66 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.66 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.66 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.66 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.66 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.66 |
| ▸ | GABRE | P78334 | 1/20 | 0.66 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.66 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.66 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.66 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7031419 | 0.98 | AR (0.69) | ARGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL7033133 | 0.89 | AR (0.56) | ARGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL11932816 | 0.89 | AR (0.59) | ARGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL7032988 | 0.88 | AR (0.73) | ARGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL7033035 | 0.87 | AR (0.58) | ARGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL7033622 | 0.86 | AR (0.76) | AR | |
| SCHEMBL25713933 | 0.86 | AR (0.72) | ARGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL12902748 | 0.86 | AR (0.76) | ARGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL547539 | 0.85 | AR (0.87) | ARGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL11932859 | 0.85 | AR (0.56) | ARGABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183274-B2 | Treatment of hyperproliferative disorders with diarylhydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-22 | — | — | US | disclosed |
| US-8110594-B2 | Diarylthiohydantoin compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-07 | — | — | US | disclosed |
| US-20100210665-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100172975-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-07-08 | — | — | US | disclosed |
| US-7709517-B2 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-05-04 | — | — | US | disclosed |
| US-20080139634-A2 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; androgen receptor antagonists with minimal agonist activity | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-06-12 | — | — | US | disclosed |
| US-20070254933-A1 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; selective androgen receptor modulators; non-steroidal, non-toxic, and tissue selective | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070004753-A1 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139634-A2 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; androgen receptor antagonists with minimal agonist activity | AR, LHCGR, KLK3 | AR 1/4885GABRP 1272/4885GABRD 1538/4885 |
| US-20070254933-A1 | Use against hormone refractory prostate cancer; 1-(3-trifluoromethyl-4-cyanophenyl)-2-thioxo-3-(substituted phenyl)-imidazolidin-5-one and spiro ring derivatives thereof; selective androgen receptor modulators; non-steroidal, non-toxic, and tissue selective | AR, NR5A1, SHBG | AR 1/4885GABRP 1935/4885GABRD 2045/4885 |
| US-20070004753-A1 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | AR, BRDT, GNRHR | AR 1/4885GABRP 480/4885GABRD 448/4885 |
| US-20100172975-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS | CDK4, CCNH, VHL | AR 113/4885GABRP 4700/4885GABRD 3973/4885 |
| US-20100210665-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | AR 2/4885GABRP 4199/4885GABRD 3464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.